Euro-BioImaging shares the news about ISIDORe at the 31st BioCity Symposium

From August 25-26, 2022, Euro-BioImaging Hub Team members attended the BioCity Symposium, where virologists and immunologists from the U.S., the U.K. and Europe presented their research. Our team was there to spread the word about opportunities for open access to European imaging infrastructures through Euro-BioImaging – including the ISIDORe User Access Fund for COVID-19, SARS-CoV-2, Monkeypox and related research topics. 

ISIDORe is a Horizon Europe funded project, lead by ERINHA, designed to support research on infectious diseases and increase pandemic preparedness. Nineteen Euro-BioImaging Nodes participate in this large-scale initiative, offering state-of-the-art imaging expertise and technologies to enhance basic research, drug discovery, diagnostics, vaccines, and clinical disease management.

At the BioCity Symposium 2022, Euro-BioImaging had a small booth, where Hub team colleagues Susanne Vainio and Camilo Guzman spoke with PhD students, PIs, researchers, and representatives from pharmaceutical & other companies from around the world about ISIDORe and the advantages of imaging for virus research. All scientists working on infectious diseases, e.g. COVID-19 are highly encouraged to visit and follow our Euro-BioImaging ISIDORe website to learn more about the ISIDORe funding opportunity, or contact us to see if their projects are eligible!

About the BioCity Symposium

BioCity Turku is an umbrella organization supporting and coordinating research on life sciences and molecular medicine in University of Turku and Åbo Akademi University. The BioCity Symposium takes place every year and covers a variety of life science and medical-related topics. This year the topic was “Solution is in Immunity” and the program covered themes in various aspects of immune regulation, immunity in novel therapies, and the role of immunity in different pathologies. In this on-site event, speakers were from all around the world, including Nobel laureate, Sir Peter Ratcliffe from the University of Oxford Francis Crick Institute, and neuroimmunologist, Professor Howard L. Weiner from Harvard Medical School.